Develops and sells branded medicines for rare or unaddressed conditions to healthcare providers and hospitals, often through medicine distributors.
10-K for FY2025, filed Apr 15, 2026We develop, manufacture and commercialize a portfolio of branded therapeutics for the treatment of rare or unaddressed diseases in the…View ↗
We promote our products directly to physicians in office settings, hospitals, and ambulatory surgical centers across our key therapeutic…View ↗
We market our products to physicians (including rheumatologists, ophthalmologists, hepatologists, nephrologists, neurologists…View ↗
Customers buy medicines through independent distributors, pharmacies and hospitals; most product sales are tied to delivery, while some are earned over time based on consumption or access. Licensed product rights bring royalties as related sales occur and, in limited cases, payments when sales milestones are reached.
10-K for FY2025, filed Apr 15, 2026The Company sells its products through independent channels which are considered its customers, including direct to retail pharmacies…View ↗
Product sales are recognized when the customer obtains control of the Company's product. Control is transferred either at a point in time…View ↗
For those contracts whereby revenue is recognized over time based upon consumption of the product, the Company either has:View ↗
For those contracts whereby revenue is recognized over time based upon the passage of time, the benefit that the customer receives from…View ↗
The Company licensed certain product rights to third parties in exchange for royalties on net sales of the respective products and, in…View ↗
10-K for FY2025, filed Apr 15, 2026
FY2025 revenue by product or service ↗$1.4B
10-K for FY2025, filed Apr 16, 2026
$1.4B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Acthar Gel
Sold outright
10-K for FY2025, filed Apr 15, 2026 |
47% |
Acthar Gel, FY2025
$677.5M Sources
|
Sold outright |
|
Xiaflex
Sold outright
10-K for FY2025, filed Apr 15, 2026 |
17% |
Xiaflex, FY2025
$246.6M Sources
|
Sold outright |
|
INOmax
Sold outright
10-K for FY2025, filed Apr 15, 2026 |
17% |
INOmax, FY2025
$244.8M Sources
|
Sold outright |
|
Therakos
Sold outright
|
0.0% |
Therakos, FY2025
$0 Sources
|
Sold outright |
|
Amitiza
Sold outright
|
4.9% |
Amitiza, FY2025
$70.6M Sources
|
Sold outright |
|
Other Product Sales
Sold outright
10-K for FY2025, filed Apr 15, 2026 |
11% |
Other Product Sales, FY2025
$160.4M Sources
|
Sold outright |
|
License
Licensed
|
2.2% |
License, FY2025
$30.7M Sources
|
Licensed |
The company markets products to physicians and other healthcare providers; pharmacies, hospitals and institutions buy directly in some cases, while other sales go through wholesalers and specialty distributors. It also contracts with payer groups to set product pricing and support access.
10-K for FY2025, filed Apr 15, 2026We promote our products directly to physicians in office settings, hospitals, and ambulatory surgical centers across our key therapeutic…View ↗
The Company sells its products through independent channels which are considered its customers, including direct to retail pharmacies…View ↗
We market our products to physicians (including rheumatologists, ophthalmologists, hepatologists, nephrologists, neurologists…View ↗
10-K for FY2025, filed Apr 15, 2026
Successor Predecessor Year Ended December 31, 2025 Year Ended December 27, 2024 Period from November 15, 2023 through December 29, 2023…View ↗
No. It lost $489.5M in FY2025.
10-K for FY2025, filed Apr 16, 2026
10-Q for Q2 FY2026, filed Aug 12, 2026
−$220.5MView ↗
8-K, filed Aug 11, 2026
Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year…View ↗
8-K, filed Aug 3, 2026
On July 31, 2026, Keenova Therapeutics plc (the “Company”) closed the previously disclosed sale of its Percocet and Endocet businesses (the…View ↗
Shrinking. Revenue fell 35% in 4 years, from $2.2B in FY2021 to $1.4B in FY2025, about 10% a year.
Branded focus
The older report described branded specialty medicines alongside specialty generics and active pharmaceutical ingredients. The latest report centers the business on branded therapeutics after separating its generic pharmaceuticals and sterile injectables businesses into Par Health.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Apr 15, 2026Specialty Brands includes innovative specialty pharmaceutical brands; and Specialty Generics includes niche specialty generic drugs and…View ↗
Our business markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology…View ↗
Our Specialty Generics segment is focused on providing our customers high-quality specialty generic drugs and APIs. Specialty Generics…View ↗
Loading...
